Loading...

Loading...

Adjust height of sidebar

KMap

People

Adjust height of sidebar

KMap

Profile

Picture of Steffan Nawrocki

Steffan Nawrocki

Professor, Clinical Translational Sciences | Director of Research | Co-Director, Translational Research | Professor, Medicine | Member of the Graduate Faculty | Associate Professor, Cancer Biology - GIDP

Collaboration(19)

Benjamin Lee
Todd Vanderah
Jason Wertheim
Anne Cress
Wei Wang

Page 1 of 4

Grants(10)

Page 1 of 2

Publications(73)

Recent

Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial

2023

immune profiling, oncolytic virus therapy, multiple myeloma, single-cell analysis, microenvironment

Targeting NEDDylation is a novel strategy to attenuate cisplatin-induced nephrotoxicity.

2023

neddylation, cisplatin-induced nephrotoxicity, drug toxicity, therapeutic strategy, kidney protection

Current Landscape of Immune Checkpoint Inhibitors for Metastatic Urothelial Carcinoma: Is There a Role for Additional T-Cell Blockade?

2023

immuno-oncology, urothelial carcinoma, t-cell blockade, cancer immunotherapy, metastatic cancer

Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapy

2020

cancer, virotherapy, epigenetics, drug resistance, oncolytic viruses

Role and mechanism of autophagy-regulating factors in tumorigenesis and drug resistance

2020

autophagy, tumorigenesis, drug resistance, cellular mechanisms, cancer therapy

Therapeutic Targeting of Autophagy for Renal Cell Carcinoma Therapy

2020

autophagy, renal cell carcinoma, therapy, therapeutic targeting, cancer

ABCG2 Overexpression Contributes to Pevonedistat Resistance

2020

cancer, drug resistance, abcg2, gene expression, pevonedistat

Autophagy: New Insights into Its Roles in Cancer Progression and Drug Resistance

2020

autophagy, cancer progression, drug resistance, cellular mechanisms, therapeutic targets

Analysis of distinct hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia

2020

mutation analysis, clinical phenotypes, therapy response, myeloid neoplasia, hotspot mutations

The novel autophagy inhibitor ROC-325 augments the antileukemic activity of azacitidine

2019

autophagy, leukemia, drug interaction, cancer therapy, cellular process